Nanogen Seeking Additional Stockholder Votes for December 15, 2004 Meeting

Dec 14, 2004, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN)
 announced today that it is continuing to seek votes or votes by proxy for its
 adjourned special stockholder meeting scheduled to reconvene on December 15,
 2004 at 2 PM PST at its offices at 10398 Pacific Center Court, San Diego,
 California.  The meeting is being held to vote on the issuance of shares of
 Nanogen common stock in connection with its proposed merger with Epoch
 Biosciences, Inc. and to amend the Nanogen certificate of incorporation
 allowing it to expand the number authorized shares.  The company continues to
 receive overwhelming stockholder support.  Of the proxies received by Nanogen,
 more than 90 percent of the shares are in favor of both proposals.  However,
 the number of shares represented by proxy remains approximately 0.6 million
 votes shy of the necessary 16.7 million votes to increase the number of
 authorized shares of Nanogen common stock.  Approval of the increase of
 authorized shares is necessary to complete the merger.
     Nanogen stockholders as of October 26, 2004 who have not voted and wish to
 do so should contact the company's proxy solicitor, Georgeson Shareholder at
 (800) 459-3121.
     About Nanogen, Inc. (Pre-Merger)
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarrays
 and analyte specific reagents to develop tests to detect mutations associated
 with genetic diseases.  The next generation instrument system, the NanoChip(R)
 400, is expected to be available in 2005.  Nanogen's subsidiary SynX offers a
 line of point-of-care diagnostic tests and is building expertise in cardiac
 related health conditions.  Nanogen's ten years of pioneering research
 involving nanotechnology may also have future applications in medical
 diagnostics, biowarfare and other industries.  For additional information
 please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including statements
 about the outcome of the special meeting of Nanogen, consummation of the
 pending merger of Nanogen and Epoch, future financial and operating results of
 the combined company and benefits of the pending merger, whether patents owned
 or licensed by Nanogen will be developed into products, whether the patents
 owned by Nanogen offer any protection against competitors with competing
 technologies, whether products under development can be successfully developed
 and commercialized, whether results reported by our customers or partners can
 be identically replicated, and other risks and uncertainties discussed under
 the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form
 10-K or Form 10-Q most recently filed with the Securities and Exchange
 Commission.  These forward-looking statements speak only as of the date
 hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.
     In addition to the specific risks identified in the preceding paragraph,
 mergers involve a number of special risks, including diversion of management's
 attention to the assimilation of the technology and personnel of acquired
 businesses, costs related to the merger and the integration of acquired
 products, technologies and employees into Nanogen's business and product
 offerings.  Achieving the anticipated benefits of the pending merger will
 depend, in part, upon whether the integration of the acquired products,
 technology, or employees is accomplished in an efficient and effective manner,
 and there can be no assurance that this will occur.  The difficulties of such
 integration may be increased by the necessity of coordinating geographically
 disparate organizations, the complexity of the technologies being integrated,
 and the necessity of integrating personnel with disparate business backgrounds
 and combining different corporate cultures.  The inability of management to
 successfully integrate the business of the two companies, and any related
 diversion of management's attention, could have a material adverse effect on
 the combined company's business, operating results and financial condition.
     The proxies held by Nanogen are revocable by the granting stockholders at
 any time prior to voting at the special meetings.  Revocations of proxies by
 Nanogen stockholders could materially impact the ability of Nanogen to
 establish a quorum and obtain approval of its proposals.
     Additional Information about the Merger and Where to Find It
     In connection with the merger of Nanogen and Epoch, Nanogen has filed a
 registration statement on Form S-4, as amended on October 26, 2004, which
 includes a prospectus of Nanogen and a joint proxy statement for each of
 Nanogen's and Epoch's special stockholder meetings, with the Securities and
 Exchange Commission.  Investors and security holders are advised to read the
 registration statement, prospectus and joint proxy statement because they
 contain important information about the proposed merger.  Investors and
 security holders may obtain a free copy of the registration statement,
 prospectus and joint proxy statement and other documents filed by Nanogen and
 Epoch with the Securities and Exchange Commission at the Securities and
 Exchange Commission's web site at  Free copies of the
 registration statement, prospectus and joint proxy statement and other
 documents filed by Nanogen with the Securities and Exchange Commission may
 also be obtained from Nanogen by directing a request to Nanogen, Attention:
 Larry Respess, Secretary, 858-410-4600.  Free copies of the joint proxy
 statement and other documents filed by Epoch with the Securities and Exchange
 Commission may also be obtained from Epoch by directing a request to Epoch,
 Attention:  Bert Hogue, Chief Financial Officer, 425-482-5555.

SOURCE Nanogen, Inc.